Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules
PONTE VEDRA, Fla., July 12, 2023 — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that it has entered into a securities purchase agreement with certain institutional investors for the issuance and sale […]
Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston
PONTE VEDRA, Fla., June 1, 2023 — Cadrenal Therapeutics, Inc., (Cadrenal or the Company) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, announced today that the company will participate in investor and partnering meetings at the BIO International Convention being held June […]
Cadrenal Therapeutics Provides First Quarter 2023 Corporate Update
PONTE VEDRA, Fla., May 10, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with today’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. […]
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference
PONTE VEDRA, Fla., May 9, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today that Quang Pham, CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference […]
Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update
PONTE VEDRA, Fla., March 30, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022. […]
Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient Population
Tecarfarin, a novel therapy designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with End Stage Renal Disease and Atrial Fibrillation, may be a new treatment option for this underserved patient population PONTE VEDRA, Fla., March 9, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing […]
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023
PONTE VEDRA, Fla., Feb. 8, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, and other Cadrenal team members will ring the Nasdaq Stock Market closing bell on […]
Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
PONTE VEDRA, Fla., Feb. 6, 2023 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place […]
Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
PONTE VEDRA, Fla., Feb. 1, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, more […]
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares of common stock at a public offering price […]
